Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29892219 | 0.84 | CYP1A2 (0.41) | LMNAKDM4EALDH1A1MAPTNQO2 | |
| SCHEMBL27474146 | 0.84 | LMNA (0.47) | LMNAELANERAD52SMN1; SMN2KDM4E | |
| SCHEMBL11219383 | 0.81 | KDM4E (0.58) | LMNAELANERAD52SMN1; SMN2KDM4E | |
| SCHEMBL4422873 | 0.81 | MPO (0.46) | LMNAKDM4EALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL3245979 | 0.81 | ADORA2A (0.51) | LMNARAD52SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL11261496 | 0.81 | LMNA (0.44) | LMNAELANERAD52SMN1; SMN2KDM4E | |
| SCHEMBL11592944 | 0.81 | KDM4E (0.43) | LMNASMN1; SMN2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL18057353 | 0.81 | ALDH1A1 (0.46) | SMN1; SMN2KDM4EALDH1A1L3MBTL1MAPT | |
| SCHEMBL12501247 | 0.79 | LMNA (0.54) | LMNAELANERAD52SMN1; SMN2KDM4E | |
| SCHEMBL7813833 | 0.78 | KDM4E (0.53) | LMNARAD52SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022272307-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022150721-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| CN-107001377-B | Pyrazolo [1,5-A] pyrimidine derivatives that there is the piperidines of inhibitory activity to replace the duplication of Respiratory Syncytial Virus(RSV) (RSV) | 爱尔兰詹森科学公司 | 2019-09-10 | — | — | CN | disclosed |
| US-9981976-B2 | Piperidine substituted pyrazolo[1,5-A]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV) | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-29 | — | — | US | disclosed |
| US-9981976-B2 | Piperidine substituted pyrazolo[1,5-A]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV) | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-29 | — | — | US | disclosed |
| US-20170349591-A1 | PIPERIDINE SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-12-07 | — | — | US | disclosed |
| US-20170349591-A1 | PIPERIDINE SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | JANSSEN INFECTIOUS DISEASES BVBA (BE) | 2017-12-07 | — | — | US | disclosed |
| CN-107001377-A | Pyrazolo [1,5 A] pyrimidine derivatives replaced to piperidines of the duplication with inhibitory activity of Respiratory Syncytial Virus(RSV) (RSV) | 爱尔兰詹森科学公司 | 2017-08-01 | — | — | CN | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| WO-2016091774-A1 | PIPERIDINE SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | WO | disclosed |
| US-8507722-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| US-8299094-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| US-20110059964-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| US-20110059964-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | US | disclosed |
| US-7659298-B2 | 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethylsulphanyl)-N-quinolin-3-ylbenzamide; 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethoxy)-N-naphthalin-2-ylbenzamide; obesity, including obesity of the non-insuline-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting | SANOFI-AVENTIS (FR) | 2010-02-09 | — | — | US | disclosed |
| US-7659298-B2 | 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethylsulphanyl)-N-quinolin-3-ylbenzamide; 2-(3-Phenyl-5-chloro-1-methyl-1H-pyrazol-4-ylmethoxy)-N-naphthalin-2-ylbenzamide; obesity, including obesity of the non-insuline-dependent diabetes patients, sleeping disorders, stroke, nausea and vomiting | SANOFI-AVENTIS (FR) | 2010-02-09 | — | — | US | disclosed |
| US-20070021459-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021459-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| WO-2005060959-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021459-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | LMNA 3529/4885ELANE 4021/4885RAD52 4824/4885 |
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | LMNA 2968/4885ELANE 2012/4885RAD52 2878/4885 |
| US-20170349591-A1 | PIPERIDINE SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | ZC3HAV1, RRP15, PIR | LMNA 2750/4885ELANE 4180/4885RAD52 3899/4885 |
| US-20110059964-A1 | PYRAZOLE DERIVATIVES AND USE THEREOF AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | LMNA 3529/4885ELANE 4021/4885RAD52 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.